Prader-Willi syndrome (PWS)

What changes during this transition

Prader-Willi syndrome is a complex multi-system genetic disorder caused by loss of expression of paternally-inherited genes on chromosome 15q11-q13 (the PWS critical region containing SNRPN, necdin, MAGEL2, MKRN3, and others). Three molecular mechanisms account for it: paternal deletion (~70%, most common), maternal uniparental disomy (~25%), and imprinting defect (~3-5%). Methylation testing of the SNRPN locus is the diagnostic gold standard — it detects all three mechanisms; follow-up testing identifies the specific subtype for prognostic and recurrence counseling. PWS presents with characteristic developmental phases. Neonatal: severe hypotonia, poor feeding, failure to thrive, cryptorchidism in males, characteristic facies — requires nasogastric feeding; hypogonadotropic hypogonadism is universal. Early childhood: gradual tone improvement followed by the defining transition to hyperphagia around age 2-5 — insatiable food seeking, food hoarding, extreme food-related behaviors. The hyperphagia drives most morbidity if access is not controlled. Adolescence and adulthood: morbid obesity if uncontrolled, short stature from GH deficiency, incomplete pubertal development from hypogonadism, learning disabilities (IQ typically 60-70), behavioral and psychiatric comorbidity (OCD-like behaviors, skin picking, rigidity, temper outbursts, depression, psychosis especially in the maternal-UPD subtype), sleep-disordered breathing including OSA, scoliosis, osteoporosis. Universal endocrine deficiencies include GH deficiency; subsets have central adrenal insufficiency (~10-15%) and central hypothyroidism (~25%). The load-bearing peptide therapy in PWS is somatropin (recombinant human growth hormone) — FDA-approved for PWS since 2000, administered from infancy or early childhood, with established benefits on growth, body composition, motor function, and cognition. Somatropin is standard of care; it is not a community peptide and is not substitutable by GHRH analogs (CJC-1295, tesamorelin) or GH secretagogues (ipamorelin), because the GH deficiency in PWS is hypothalamic in origin and somatropin bypasses the broken axis that those upstream peptides depend on. The hyperphagia-targeting therapy landscape is active but no FDA-approved hyperphagia-specific therapy exists yet: setmelanotide (Imcivree, MC4R agonist — FDA-approved for POMC/LEPR/PCSK1 deficiency in 2020 and Bardet-Biedl syndrome in 2022) was studied in PWS but the DAYBREAK Phase 3 trial did not meet primary endpoint in 2022; DCCR (dicamba, oral KATP-channel opener) DESTINY-PWS missed primary endpoint 2022 and was resubmitted to FDA via subgroup analysis 2024; intranasal oxytocin and the PWS-specific oxytocin analog carbetocin have generated significant family interest but trial data is mixed; semaglutide and other GLP-1 agonists are being used off-label and studied in trials with real coordination-of-care complexity (FDA boxed warning for MTC/MEN2, adolescent prescribing weight, PWS-specific GI motility considerations). The strict food security environment — locked food access, supervised meals, structured routine — is the load-bearing non-pharmacologic intervention in PWS and stays in place regardless of any pharmacotherapy on board. Standard endocrine replacement covers the specific deficiencies: testosterone or estrogen + progesterone for hypogonadism, hydrocortisone if central adrenal insufficiency, levothyroxine if central hypothyroidism, calcium + vitamin D + DEXA for bone health. Family advocacy organizations (Foundation for Prader-Willi Research, International Prader-Willi Syndrome Organisation, PWS-USA, FPWR) provide patient assistance navigation, family support, and trial information. The Juno editorial substrate frame: somatropin IS the peptide therapy in PWS — it is named here explicitly as the load-bearing FDA-approved standard of care rather than elevated as a community peptide. Community GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) are mechanistically the wrong direction for PWS and the substrate addresses that error directly. General-purpose anti-aging substrate (NMN and the like) doesn't track to the PWS biology and displaces attention from interventions that actually move outcomes. BPC-157 has no PWS-specific characterization. Semaglutide and other GLP-1 agonists are an active off-label conversation that needs to happen with a PWS-specialty endocrinologist, not a general weight-loss clinic. This browse entry deliberately does not elevate community peptides for PWS — the load-bearing peptide therapy (somatropin) is named in this note, and the hyperphagia-targeting trial landscape is named honestly; surfacing community peptides as discovery cards would misframe a coordination-heavy lifelong syndrome where the family's primary work is partnering with a multidisciplinary PWS team, maintaining the food security environment, and tracking the active hyperphagia-targeting trial landscape through PWS advocacy organizations. Sixty-third deliberate non-elevation of community peptides.